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Asthma is a chronic disease which causes recurrent breathlessness affecting 300 million 
people worldwide of whom 250,000 die annually. The epigenome is a set of heritable 
modifications and tags that affect the genome without changing the intrinsic DNA 
sequence. These marks include DNA methylation, modifications to histone proteins 
around which DNA is wrapped and expression of noncoding RNA. Alterations in all 
of these processes have been reported in patients with asthma. In some cases these 
differences are linked to disease severity and susceptibility and may account for the 
limited value of genetic studies in asthma. Animal models of asthma suggest that 
epigenetic modifications and processes are linked to asthma and may be tractable 
targets for therapeutic intervention.
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Asthma is a chronic disease of the airways 
that causes reversible difficulty in breathing 
through bronchoconstriction, mucus hyper-
secretion and airway remodeling and afflicts 
over 300 million people worldwide [1,2]. 
Asthma is a heterogeneous disease that can 
be atopic or nonatopic, and demonstrates 
various subclinical phenotypes [3]. The vari-
ety in asthma phenotypes provides chal-
lenges to treatment as phenotyping asthma is 
neither easy nor readily affordable. This may 
account for the failure of many drugs to pro-
ceed beyond early Phase II studies as patients 
are not adequately phenotyped [4]. Until bet-
ter matching of phenotypes to driver path-
ways or molecules is achieved, phenotype-
specific treatment using expensive biologicals 
for example will not be cost effective [5].
The adaptive immune response in asthma 
is regulated by CD4+ T-cell subsets. The 
principle two subtypes of T helper cells are 
type 1 (Th1) and type 2 (Th2) which drive 
the cellular and humoral immune responses 
respectively [6]. Asthma is characterized at the 
cellular level by hyper-responsiveness of Th2 
in both atopic (allergic) and nonatopic asth-
matics [7,8]. In susceptible individuals, the 
Th2 response is stimulated by environmental 
effectors including allergens, temperature, 
humidity and air pollution [6]. This process 
of activation in allergic asthma begins with 
the airway epithelium, which upon stimula-
tion releases factors which subsequently acti-
vate phagocytic cells and together they enable 
the activation of Th2 cells [6]. Th2 cells are 
able to self-propagate by the release of IL-4; 
drive infiltration of eosinophils by releas-
ing IL-5 and activate B cells, which release 
antibodies against the allergens, by releasing 
IL-13 [6]. IL-13 also plays a major modulat-
ing role on airway epithelial cells increas-
ing the production of mucins, periostin and 
other mediators [9].
Other T-cell subtypes also play a role in 
asthma, including the balance of the IL-
17-producing Th17 cells and Treg. Th17 cells 
are associated with neutrophilic inflamma-
tion [10] and have been shown to contribute 
to severe asthma and relative corticosteroid 
insensitivity [11]. By contrast, Treg cells are 
able to repress cytokine release and prolifera-
tion from other T-cell subtypes [12], including 
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Th17 cells. The balance of Th17/Treg cells in periph-
eral blood of asthmatics is skewed toward Th17 [13,14] 
which inhibits the resolution of inflammation and 
increases neutrophilic infiltration.
Generally asthma is well controlled by inhaled cor-
ticosteroids and bronchodilators; however, 10% of 
patients suffer from ‘severe’ asthma that is poorly con-
trolled even by high doses of inhaled and oral steroids 
and other treatments such as theophylline, anti-IgE or 
leukotriene receptor agonists [5]. While asthma can be 
controlled it cannot be cured, therefore the develop-
ment of new treatments and identification of novel 
drug targets are a priority in asthma research.
Asthma has been shown to have a heritable compo-
nent in large twin studies [15], and by using polygenic 
heritability estimates [16]. A heritable phenotype can be 
the product of many different mechanisms; these can 
be divided into two categories: those that change the 
DNA sequence and those that do not. To date much of 
the research into the heritability of asthma has focused 
on the changes to the DNA sequence, however large-
scale genome-wide association studies (GWAS) have 
only identified a handful of genetic changes or SNPs 
linked to asthma which are highly significant on a 
population scale but not predictive at the individual 
level [17,18]. It is also unknown whether these changes 
are causative and it is likely that causality will be linked 
to different environmental exposures in selected sub-
phenotypes of asthma.
Research is therefore becoming more focused on her-
itable characteristics that are not due to altered DNA, 
termed epigenetic modifications, and the sum of these 
modifications termed the epigenome. These epigenetic 
processes include modifications to DNA-binding his-
tones, applying methylation marks to cysteine in DNA 
and noncoding RNAs such as miRNA [19].
To date studies of the epigenome in asthmatics have 
demonstrated changes in monocytic DNA methyla-
tion [20] and histone modification [21], blood leuko-
cyte [22] and eosinophil [23] methylation, CD4+ T-cell 
histone modifications [24–26] and smooth muscle and 
T-cell miRNA expression [27,28] and histone acetylation 
at distinct residues [29] compared with their healthy 
controls. What these data are unable to show is whether 
these changes cause, or are a result of, asthma although 
animal models may help resolve this issue.
Various techniques have been developed to inves-
tigate epigenetic regulation of gene expression. These 
include using methods such as chromatin immunopre-
cipitation (ChIP) to confirm specific histone modifica-
tions at single gene promoters or at a genome-wide level, 
or to map the location of specific histone modifications 
with chromatin structure (using ChIP-Seq [24] and 
DNase 1 hypersensitivity [30]), measuring DNA meth-
ylation (bisulfite sequencing using array or next-gen-
eration sequencing [31]) and expression profiles of non-
coding RNA (gene array or PCR-based analysis [32]). 
There is growing number of available tools which can 
alter the extent to which cells modify histones and 
methylate DNA which means we can begin to inves-
tigate the role of epigenetic modifications in asthma 
and identify potential new therapeutics. It is important 
to note that each cell type has a distinct epigenome 
and it is important to examine changes with disease 
in single cell types [33] or to use bioinformatic tools to 
deconvolute data to allocate to single cells [23].
The encyclopedia of DNA elements (ENCODE [34]) 
a project to catalog the regulatory elements in human 
cells and its follow-up of the Epigenome Road-
map [35] are two projects that have built reference 
epigenomes for 127 tissue and cell types [36,37]. The 
Epigenome Roadmap has been able to gather reference 
epigenomes for a variety of T-cell subtypes and B cells 
and this information is ripe for analysis if compared 
with more asthmatic samples.
Histone modifications
Nucleosomes are octomeric complexes of histone pro-
teins which bind to DNA. Each octomer comprises 
two pairs of the histones H2A and H2B and two 
pairs of the histones H3 and H4 [38]. 146bp of DNA 
is wrapped and stored around each nucleosome which 
are tethered together by histone H1 [39].
Histones serve multiple functions in normally func-
tioning cells: they store DNA safely [38], they can stop 
transcription by tightly coiling DNA [40] and they can 
encourage transcription by forming a suitable local 
structure to enable accessibility of transcription fac-
tors [41]. When the DNA is loosely bound to the his-
tones in what is known as the euchromatin or ‘open’ 
state, transcription may readily take place [42]. How-
ever, when histones are tightly bound to DNA, known 
as the heterochromatin or ‘closed’ state, DNA poly-
merase II and transcriptional activators are unable to 
readily access DNA and transcription is limited. The 
strength of binding between histones and DNA can 
be controlled by post-transcriptional modifications to 
the N-terminal tail of the histone proteins, usually per-
taining to the addition of acetyl or methyl groups to 
amino acids such as lysine and arginine [43].
These modifications can change the charge of the 
histones which either repels DNA if more negatively 
charged, or attract DNA if more positively charged [44]. 
Alternatively, these modifications on histones residues 
form epitopes that enable other proteins including 
transcription factors and transcriptional co-factors 
to be recruited to the site of original driver modifica-
tion in a temporal manner. The site-specific and time-
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dependent formation of these histone modifications, 
including acetylation and methylation, is termed the 
histone code or language. The histone code is ‘read’ by 
proteins termed readers which in turn help recruit the 
transcription factors. Although the histone code is a 
useful concept, the myriad numbers of different com-
binations of modifications that can occur means that 
this has not been proven. In addition, phylogenetic 
analysis of histone deacetylases (HDACs) and histone 
acetyltransferases (HATs) suggests that these existed 
before histones implicating that acetylation of nonhis-
tone proteins will play an important role in regulat-
ing cellular function [45]. Indeed, it is now clear that 
many cytoplasmic and nuclear proteins including tran-
scription factors, signaling molecules and structural 
proteins are acetylated.
Histone acetylation
The role of histone acetylation
Histone acetylation is primarily associated with 
the euchromatin state (loosely packed DNA) and 
increased transcription as acetylation is associated with 
a positive electrostatic charges of the histones, repel-
ling the DNA and increasing the DNA’s accessibility 
and ability to be transcribed [44,45]. Multiple lysine 
residues on a single histone subunit can be acetylated. 
For example acetylation on histone 3 lysine 9 (H3K9) 
and lysine 27 (H3K27) have been shown to increase 
transcription [45,46].
Histone acetylation in asthma
HAT activity is increased in asthmatic biopsies in both 
adults [47] and in children [48] and the HAT/HDAC 
ratio alters according to asthma severity. Histone 3 
lysine 27 (H3K27) acetylation (H3K27Ac) is asso-
ciated with the enhancer regions of genes that are 
actively being expressed [49]. H3K27 is acetylated by 
the HAT Gcn5. This tag has been shown to be an 
important component of the histone code and re-
analysis of asthma GWAS achieved greater predictive 
power by only using SNPs in coding or regulatory 
regions and linking this to H3K27Ac and H3K4me1 
marks in different cell types [25]. These two marks are 
critical for TH2 cell accumulation and differentiation 
in asthma although the H3K4me2 mark was the most 
highly enriched at sites encoding transcription factors 
and microRNAs [24].
Th2 cells and follicular helper T cells (Tfh cells) 
are the major producers of IL-4 but require distinct 
and overlapping, molecular mechanisms [50]. The 
DNA methylltransferase Dnmt3a also regulates Th2, 
particularly IL-13, expression. Loss of Dnmt3a leads 
to decreased DNA methylation and changes in the 
H3K27Ac status at the IL-13 locus and is associated 
with increased lung inflammation in a mouse model 
of asthma [51].
The deposition of acetyl tags appears less selective 
than the removal of these marks by HDACs as deter-
mined in a genome-wide acetylome analysis [52] HDACs 
remove acetylation marks from both histones and from 
nonhistone proteins such as the glucocorticoid receptor 
(GR) and other transcription factors. A combination of 
GR deacetylation and changes in histone acetylation 
status are involved in the mechanisms by which cor-
ticosteroids reduce the expression of NF-κB-activated 
inflammatory genes [53]. Defective HDAC2 expression 
and activity is found in some corticosteroid-insensitive 
disease cells/tissues and models and corticosteroid sen-
sitivity can be restored by increasing HDAC2 expres-
sion [40,54]. This is highly relevant to severe asthma, the 
form of asthma that remains steroid insensitive.
HDAC1 function is vital to the repair and remodel-
ing of the airway epithelium and epithelial cell growth 
stops upon HDAC1 inhibition [55]. Epithelial cells 
form the principle barrier between the lung and the 
environment and induce the first stages of the immune 
response during an asthma attack. Increased airway 
epithelium and remodeling is associated with asthma 
severity [56] and correspondingly increased HDAC1 is 
found in patients with severe asthma compared with 
normal patients and may represent a biomarker to 
distinguish between severe and nonsevere asthma [57].
In addition to enabling general switching between 
the eu- and hetero-chromatin states, site-specific his-
tone acetylation also promotes transcription factor 
binding. One key example for asthma is the binding 
of the pro-inflammatory transcription factor NF-κB. 
Acetylation of histones at H3K9 and K27 is recog-
nized by histone code readers including the bromodo-
main containing family of proteins. One such protein, 
Brd4, contains two bromodomain regions and is able 
to bind acetylated histones and acetylated p65 (part 
of the NF-κB complex). NF-κB p65 activation is con-
trolled by its acetylation status, for example, on K310 
and binding of Brd proteins is important for control-
ling full NF-κB activity in cell-dependent manner [58]. 
Thus, Brd proteins can bring together nucleosomes 
and nuclear transcription factors to increase prolifera-
tion and inflammation [59,60]. Acetylated histone’s abil-
ity to bring together DNA and transcription factors 
positions it as vital pivot for the expression of specific 
inflammatory genes regulated by NF-κB.
Potential asthma therapies targeting histone 
acetylation
As histone (de)acetylation plays a role in the activa-
tion of inflammation and its resolution, drugs that 
target histone acetylases and deacetylases have been 
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investigated in asthma (Table 1). Pan-histone deacety-
lase inhibitors, such as Trichostatin A (TSA) and Vori-
nostat, have been used as cancer treatments and have 
been investigated in asthma although their efficacy at 
reducing inflammation remains controversial prob-
ably due to their lack of selectivity [61]. TSA reduces 
inflammation in human precision cut lung slices and 
in in vivo mouse models [61]. In two recent studies TSA 
treatment reduced inflammation, IL-17 and T-helper 
cell number while increasing Treg-cell activation [62]. 
Furthermore, the expression of TGF-β in the broncho-
alveolar lavage fluid was increased following HDAC 
inhibition in a mouse model of asthma [62,63]. These 
changes were associated with increased acetylation 
at the TGF-β promoter. It is also of interest to note 
that this study also showed that severity of asthma was 
linked to HDAC9 [62].
Vorinostat was the first HDAC inhibitor approved 
by the US FDA for cutaneous T-cell lymphoma. It was 
demonstrated to be beneficial in graft-versus-host dis-
ease (GVHD) as it increased activation of Tregs [63]. 
HDAC inhibition reduced plasma cytokine levels 
without inhibiting T-cell responses to nonspecific 
stimuli allowing the immune system to continue to 
function.
While pan-HDAC inhibitors show anti-inflamma-
tory effects in some studies, other studies are unable to 
replicate these effects [78–81]. There is also evidence that 
HDAC inhibitors can in fact enhance inflammation 
through NF-κB-driven inflammatory gene transcrip-
tion [60–62]. The use of HDAC inhibitors as a potential 
treatment for asthma is further complicated by the role 
of HDAC proteins in the anti-inflammatory response 
to glucocorticoids [61]. As reduced HDAC2 activity 
is associated with steroid insensitivity, the activation, 
rather than inhibition of HDAC2, would be benefi-
cial. The drug theophylline has been associated with 
improved steroid sensitivity in several studies and has a 
putative mechanism of action which involves restoring 
HDAC2 activation [82]. It has been shown to improve 
steroid sensitivity in COPD which may be similar in 
mechanism to asthma [83].
The multiple roles of histone acetylation in regu-
lating cell function and cell division [84] mean that 
pan-HDAC inhibitors or activators will almost cer-
tainly have large negative side effects if used clinically. 
More recently, a link between HDAC inhibition of 
STAT5-activated gene expression and Brd functions 
has been reported [85]. The consensus is that more 
work is needed to explore how epigenome modifying 
drugs will effect acetylation mechanisms in airways 
disease [86,87], in order to overcome the principle issue 
of targeting the change in acetylation status to the 
relevant genes.
Targeted modifications to histone acetylation have 
been undertaken in neurones using modified transcrip-
tion factors to increase acetylation at the Fosb gene [88]. 
If targeted transcription factors can be used to increase 
acetylation then it is possible that they can be used to 
decrease acetylation as tools and potentially therapies. 
Many histone modifications including H3K9 acetyla-
tion H3K27me3, H3K9me1 and H4K8ac have been 
regulated in vitro by using light-inducible transcrip-
tional effectors (LITEs). These are a set of blue-light 
activated restriction enzymes that have been developed 
for high level temporal and spatial control of target 
gene expression and may be used to target specific his-
tone effectors and thereby modify the epigenome. For 
example, H3K9 acetylation was reduced twofold at 
the target gene Grm2 using this method resulting in 
repression of Grm2 [89]. This approach may pave the 
way for epigenome modification in vivo.
The bromo and extraterminal (BET) family of pro-
teins recognise lysine acetylation on many proteins 
including histones [90], which aids the recruitment of 
transcription factors and the RNA polymerase tran-
scription complex to enable gene transcription [91]. The 
BET protein Brd4 binds to acetylated histones in the 
euchromatin state [92] but can also interact with other 
nonhistone proteins [60] such as NF-κB [93]. Mimics of 
BET proteins such as JQ1 [94] reduce asthma relevant 
processes including IL-1β-induced inflammation [95] 
and proliferation [96]. JQ1 and similar compounds are 
currently being investigated as anticancer treatments 
in man [64] but the broad action of the BET family 
inhibitors may require the development of novel com-
pounds with different selectivity. Alternatively, the use 
of inhaled delivery to the airways, linked to improved 
lung retention and rapid systemic breakdown, may 
reduce the side effect profile to enable thier use in 
asthma.
Histone methylation
Lysine residues in histone tails can be modified to have 
between one and three methyl groups: mono, di or tri-
methylation. The functional effect of the modification 
depends upon the residue targeted and the number of 
methyl groups added.
The role of H3K4 methylation
Genes have pretranscriptional regions before tran-
scriptional start site and by modifying this region 
control can be exerted over gene expression. His-
tone modifications in this region can either inhibit 
or activate transcription; known as a bivalent gene 
or effect. When two contradictory acting histone 
modifications are bound at the same promoter the 
inhibitory marker takes precedence [97], leading 
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Table 1. List of epigenetic modifying tool compounds. 
Epigenetic mark Target Tool compound Affected process
Histone acetylation  
 
 
Pan histone deacetylase 
inhibitors
Trichostatin A Cancer treatment reduced IL-17 and T 
helper cell number, reduced TGF-β in mouse 
BAL [62,63]
Vorinostat Cancer treatment and graft vs host disease [63]
BET domain mimics 
– block readers of 
acetylation
JQ1 Prevent cell cycle progression and 
investigated as an anticancer treatment [64,65]
Histone methylation:   
– Histone 3 lysine 4 (H3K4) SETD7 PFI-2 H3K4 is linked to activation of inflammatory 
responses [26,66]
– Histone 3 lysine 9 (H3K9) G9a (H3K9 
methyltransferase)
UNC0642 Macrophages and dendritic cells of 
asthmatics undergoing allergen exposure 
may benefit from the inhibition of H3K9 
methyltransferases, to prevent activation of 
the inflammation
 JMJD2 H3K9 demethylase ML324 Decrease the effects of Herpes virus in 
mice [67]








Compound 12d Additive effects with HDAC inhibitors on 




DNMT1 complexes  DNMT inhibitors may return T cells to a Th1 
phenotype in asthma [70]
DNMT1/PCNA Peptide inhibitor - 
163–174
Target DNA methylation at specific regions [71]
DNMT1/USP7 Peptide inhibitor - 
561–567
Target DNA methylation at specific regions [71]
DNMT1/STAT3 Peptide inhibitor - 
683–174
Target DNA methylation at specific regions [71]
DNMT1/CFP1 Peptide inhibitor - 
1081–1097
Target DNA methylation at specific regions [71]
 miRNAs miR-34 mimic MRX34 Inhibits tumor growth [72]




Enter effector T cells and suppressing allergic 
contact dermatitis and promoting antigen-
specific tolerance in mice [74]
miR-9 miR-9 antagamirs Inhibition of miR-9 increased PP2A activity 
and GR nuclear translocation in macrophages 
and restored steroid sensitivity in multiple 
mouse models of steroid-resistant AHR [75]
miR-145 miR-145 antagamir miR-145 antagamir inhibited eosinophilic 
inflammation, mucus hypersecretion, Th2 
cytokine production and AHR in murine 
model of asthma [76]
AHR: Airways hyper-responsiveness; BET: Bromo and extraterminal domain; GR: Glucocorticoid receptor; LPS: Lipopolysaccharide.
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to transcriptional pause where the transcriptional 
complex is bound to the promoter but is halted and 
unable to generate RNA. Elongation will begin as 
soon as the inhibitory mark is removed and the RNA 
polymerase II is able to proceed. Di-methylated 
histone 3 lysine 4 (H3K4me2) marks are commonly 
found at poised and active enhancer regions [98].
H3K4 methylation in asthma
Histone methylation has been linked to both T-cell 
differentiation and function, particularly for the 
control of CD4+ T-cell differentiation [26]. T-cell 
fate is principally controlled by the transcription 
factors T-BET (Th1 cells) and GATA3 (Th2). The 
ability of these transcription factors to regulate 
their target genes is dependent on their associated 
methyltransferase activity [66].
IL-4, IL-5 and IL-13 are all coded for in a single 
stretch of DNA on chromosome 5 and are sepa-
rated by the RAD50 gene. RAD50 encodes a DNA 
repair protein [99] and has four conserved enhancer 
regions in its introns. H3K4me1 modifications 
at these enhancer regions, are increased in T cells 
from asthmatic patients [24] and are associated with 
transcriptional pause. Further environmental sig-
nals, such as antigen recognition, trigger other 
transcription factors to resolve the pause and enable 
transcription [100]. H3K4me3 is linked to increased 
transcription of both IFNG and IL-4 [26].
Combining H3K4me2 ChIP-Seq with GWAS in 
subsets of human peripheral blood T cells (naive, 
T
H
1 and Th2) has shown that the differentiation of 
Th2 cells is marked by an increased enrichment of 
H3K4me2 at SNPs within the promoters and cis-reg-
ulatory regions of asthma-associated genes including 
CCR4 and CCL5 [24]. CCR4 receptors have shown 
to be vital in the recruitment of Th2 cells to the 
lung [101] and CCL5 is chemotactic for T cells [102]. 
T-cell studies have found patterns of H3K4 dimeth-
lyation at enhancers during Th2-cell differentiation 
that support a pathogenic role in asthma [24]. Using 
gene ontology software, it was shown that genes asso-
ciated with mitosis and regulation of apoptosis were 
most differentially enriched in asthmatics.
Potential asthma therapies targeting H3K4 
methylation
At present no therapeutically licenced drugs exist that 
target histone methylation, although new compounds, 
such as PFI-2 that target histone methylation have 
been developed [103]. PFI-2 competitively inhibits the 
SET domain containing (lysine methyltransferases) 7 
(SETD7), a methyltransferase for H3K4 [104], which 
may play a role in cell stress and inflammation as SETD7 
is able to activate expression at NF-κB binding sites.
As H3K4 methylation is associated with the activa-
tion of inflammatory and proasthmatic cytokine pro-
duction preventing histone methyl-transferase activity 
may be of future benefit to patients. However, as with 
histone acetylation the ability to target histone modifi-
cations at specific sites, such as the asthma SNPs would 
be the ultimate goal of therapeutic research [24].
The role of H3K9 methylation
The presence of H3K9me3 at gene promoters is associ-
ated with gene repression including that of inflamma-
tory genes [105]. H3K9me3 acts by preventing RNA Pol 
II binding to target gene promoters.
H3K9 in asthma
Airway remodeling is a cardinal feature of asthma and 
the control of it is mediated in part by VEGF which in 
asthmatics is hypersecreted by human airway smooth 
muscle cells (HASM). In asthmatic HASM there is a 
decrease in the H3K9me3 repressive complex at the 
promoter of the VEGF gene. The methyltransferase 
G9a is vital for repression of VEGF in healthy patients 
HASM [106].
JMJD2D is an H3K9me3 demethylase which removes 
H3K9me3 repression complexes, activating transcrip-
tion [107]. In dendritic cells and macrophages, JMJD2D is 
induced by external stimulus and is required for Mdc and 
Il12b transcription. This is an example of how H3K9me3 
is able to broadly control functional enhancers linked to 
cell-type-specific gene expression [105].
Potential asthma therapies targeting H3K9
Inhibitors of both H3K9 methyltransferases and 
demethylases have been recently developed. These 
Epigenetic mark Target Tool compound Affected process
miRNAs (cont.) miR-126 miR-126 antagamir Blockade of miR-126 suppressed Th2 
responses, inflammation, AHR, eosinophil 
recruitment and mucus hypersecretion in 
mouse model of asthma via suppression of 
GATA3 expression [77]
AHR: Airways hyper-responsiveness; BET: Bromo and extraterminal domain; GR: Glucocorticoid receptor; LPS: Lipopolysaccharide.
Table 1. List of epigenetic modifying tool compounds (cont.). 
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tools that target the enzymes G9a and JMJD2D pre-
vent activation of the inflammation in macrophages 
and dendritic cells of asthmatics undergoing allergen 
exposure [106]. Similar treatments may be of use to limit 
airway remodeling in HASM cells [106]. UNC0642, a 
recently discovered inhibitor of G9a, may be a useful 
tool in future studies [108]. However, G9a inhibition 
may result in detrimental side effects. For example, 
while knockout of G9a reduces inflammation in cell 
culture it is essential for embryogenesis [106,109]. There-
fore further research will be required to allow more 
targeted inhibition of histone methylation at specific 
gene loci, for example understanding how H3K9 
methylation is targeted to specific genes.
The role of H3K27 methylation
H3K27me3 can have different functional effects on 
gene transcription depending on the location of the 
histone relative to the gene [110]. First, when the modi-
fied residues are located within the body of the gene, 
H3K27me3 inhibits gene expression; however, when 
H3K27me3 is found at the transcriptional start site it 
is associated with the expression of bivalent genes and 
transcriptional pausing. Finally H3K27me3 in the 
promoter region of a gene is associated with an increase 
in transcription [110].
H3K27 methylation in asthma
Trimethylation of H3K27 can be catalyzed by EZH2, 
which is a subunit of the polycomb repressive complex 
2 [97] and has been associated with gene repression. 
EZH2 is a histone lysine methyltransferase which is 
highly specific to K3K27, and is vital for CD4+ dif-
ferentiation and activation [111]. H3K27me3 blocks 
the production of IL-4 in Th1 cells while in Th2 cells 
the gene body of the repressed IFNG was marked by 
H3K27me3 [111].
The ubiquitously transcribed tetratricopeptide 
repeat, X chromosome (UTX) and JMJD3 are H3K27-
specific demethylases [112] which remove the H3K27me3 
repressive marks [113]. JMJD3 and UTX regulate chro-
matin complexes [114], macrophage plasticity in mice, 
pro-inflammatory gene regulation [115] and T helper 
cell development [112]. JMJD3 knockdown in THP-1 
monocyte cell line and macrophages decreased the 
effect of inflammatory signaling pathways as measured 
by gene array, by increasing H3K27me3 at the promot-
ers of NF-κB induced genes and many members of the 
CD40 and chemokine signaling pathways [113,114].
In a mouse model of asthma, Th2 cells from and 
Ezh2-/- mice were adoptively transferred to wild-type 
mice which underwent a subsequent acute ovalbumin 
(OVA) challenge. The transfer of Ezh2-KO Th2 cells 
resulted in in eosinophilia, IL-4, IL-5 and IL-13 and 
mucus hyperproduction and enhanced asthma-like 
pathology [111]. There was also overproduction of IFN-γ 
indicating activation of both the Th1 and Th2 pathways 
which is often seen in human asthma. However, other 
studies suggest that blockade of Ezh2 is not sufficient to 
prevent the production of inflammatory cytokines [111].
Epithelial cells respond to IL-4, by demethylating 
H3K27me3 at the ALOX15 gene promoter increas-
ing its transcription [116]. ALOX15 oxygenates poly-
unsaturated fatty acids to synthesize potent signaling 
mediators and has been shown to increase in expression 
with increasing severity of asthma [117]. The ALOX15 
promoter is associated with H3K27me3 and its expres-
sion is regulated by UTX [117]. Whether this is causal 
in asthma, however, is unknown. Tool compounds for 
this demethylase include the nonselective inhibitor 
GSK-J4 [68].
Potential asthma therapies targeting H3K27 
methylation
As the loss of EZH2 is linked to the asthma pheno-
type inhibiting the demethylases JMJD3 or UTX may 
be beneficial in asthma (Table 1). There is currently a 
selection of new tools and potential drugs available 
which will target the H3K27me3 modifying enzymes 
(JMJD3, UTX, EZH2) such as 1-substituted cyclo-
propylamine [118] an irreversibly binding, nonspecific 
H3K27 demethylase inhibitor. Blocking JMJD3 in 
macrophages with the inhibitors GSK-J1 and GSK-J4 
prevents LPS-induced inflammation [68].
The phenelzine analog compound 12d is a lysine-spe-
cific demethylase inhibitor, it has been shown to have 
additive effects when used with HDAC inhibitors in 
inhibiting cell proliferation and may be useful to inhibit 
inflammatory cytokines as well [69]. Compounds target-
ing H3K27 methylation have not been therapeutically 
assessed, nor are all their effects understood. However 
they do provide potential tools to investigate role of 
histone methylation in inflammatory gene expression.
Generally histone demethylation is essential for dra-
matic changes in epigenetic states such as in cell differ-
entiation of T cells; however, demethylase proteins that 
antagonize repression such as JMJD3 are expressed in 
terminally differentiated cells. JMJD3 has a separate role 
in chromatin remodeling which is independent from its 
H3K27-demethylase function. This demonstrates a role 
for JMJD3 outside of epigenetic modifications and must 
be taken into account when using drugs to modify the 
effects of them [112].
DNA methylation
The role of DNA methylation in asthma
DNA methylation is generally associated with gene 
repression and occurs at complementary pairs of cys-
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teine residues which are directly followed by guanine 
(CpG) in mammals [119]. DNA methylation regulates 
many processes including cell fate, inactive X chro-
mosomes and gene-specific activation and silenc-
ing. During cellular replication, the methylation 
marks are maintained by the DNA methyltransfer-
ase DNMT1 which converts hemimethylated DNA 
into fully methylated DNA [120]. During germ cell 
development, cell-specific methylation is totally 
removed and is then re-established by DNMT3A and 
DNMT3B, which can give rise to specific maternal 
and paternal gene expression profiles, termed genetic 
imprinting [119].
The importance of DNA methylation in allowing 
transcription is vital in the activation of the asthmatic 
immune response and restricting the DNA methylome 
in some cells may be of therapeutic benefit to patients. 
Naïve CD4+ T cells show methylated CpG regions in 
the IL-4 promoter which limits transcription. After 
house dust mite stimulation, DNA demethylation 
increases at the IL-4 promoter in cells from patients 
with bronchial asthma, but not in controls [31]. To 
enforce differentiation to Th2 type CD4+ T cells, 
Th1 type gene promoters, such as IFNG, are inhib-
ited by enhancer DNA methylation. This is linked to 
decreased expression of IFN-γ in CD4+ T cells [70]. 
Th2 cells can, however, reactivate the production of 
IFN-γ by demethylating the IFN-γ promoter, demon-
strating the cell’s epigenetic plasticity. The changes are 
mediated by GATA3 and T-bet, both of which are vital 
to T-cell development and differentiation [121].
DNMT1, the DNA methyltransferase that main-
tains DNA methylation, appears to be self-regulating in 
mouse asthma models. Following allergic stimulation, 
DNMT1 expression in the lung, trachea and broncho-
alveolar lavage fluid cells was decreased in tandem 
with DNMT1 promoter DNA hypermethylation [122]. 
Studies examining zebrafish development have high-
lighted the cross-talk that occurs between epigenetic 
processes. The gene lef1 is controlled by a network that 
includes Dnmt3 and G9a, the H3K9 methyltransfer-
ase. G9a and Dnmt3 seem to function simultaneously 
to silence critical regulators of cell fate [123].
The DNA methylation status at asthma-relevant 
SNPs within the IL-4R gene is associated with an 
increased risk of asthma at age 18 if the site was more 
highly methylated [22]. There are significant links 
between methylation status at 36 loci in peripheral 
blood eosinophils and the presence of serum IgE [23]. 
The implicated loci included eosinophil products and 
phospholipid inflammatory mediators and provide 
a list of potential new biomarkers and target genes 
for drug development against allergy and potentially 
allergic asthma.
Potential asthma therapies targeting DNA 
methylation
No DNA methylation targeting compounds have 
been investigated in relation to asthma per se (Table 1), 
however cancer drugs that target DNMT1-CFP1 and 
DNMT1-Stat3 complexes are able to demethylate 
specific regions of DNA associated with tumor sup-
pressor genes without causing global DNA hypometh-
ylation [71]. Drugs have been designed which are able 
to block DNMT1 complexes forming with HDAC1, 
STAT3, PCNA, CFP1 and USP7 which gives a broad 
scope for many other investigations into DNA meth-
ylation in T-cell differentiation. In addition to this 
targeting of DNMT at specific genes, knock-in mice 
that caused promoter hypermethylation at the INSL6 
and the p16 genes and transcriptional suppression by 
adding a cis-acting regulatory element that attracts 
DNMT have been developed. This method could be 
applied to other genes as well [124].
Sections of RNA have been shown to modify the 
effects of DNMT. For example a region of RNA from 
the CEBPA locus (ecCEBPA) is able to interact with 
DNMT1 and prevent the methylation of its gene and 
increase the transcription of CEBPA. If this effect can 
be shown in other genes it may suggest a novel mecha-
nism by which expressed RNA controls DNA meth-
ylation and will be a model to base new treatments 
off [125].
It is possibly that hyper and hypomethylation is 
modifiable so it is important that DNMT inhibitors 
may have beneficial effects in reducing allergen sen-
sitization in asthmatics through the reversal of IFN-γ 
repression and the return of T cells to a Th1 pheno-
type [70]. At present DNMT1 inhibitors have been con-
sidered as an anticancer treatment, however making 
sure that they only inhibit hypermethylation of tumor 
suppressor genes without demethylating oncogenes is a 
technical challenge. The development of asthma thera-
peutics will also contain similar challenges. Excitingly 
as DNMTs act in complexes with other transcription 
factors, and their targeting is linked to the complexes 
they are associated with, such G9a [126], HDAC1 [127] 
and PCNA (proliferating cell nuclear antigen) [128], 
DNMT inhibitors have the potential to inhibit specific 
DNMTs that are associated with inflammation while 
leaving global DMNT activity unaffected.
miRNA in asthma
Noncoding RNAs (ncRNA) are functional RNAs 
which are not transcribed and may be important in 
respiratory disease [129]. They can be broadly subclas-
sified into three groups; housekeeping RNAs (ribo-
somal, transfer, splicesomal), long noncoding (pseudo-
genes, intronic, intergenic) and the small noncoding 
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RNAs (PIWI-associated RNA, endogenous siRNA, 
microRNAs). microRNAs (miRNAs) are the most 
studied in respiratory disease, including asthma, cystic 
fibrosis [130] and lung carcinoma [131].
miRNAs are ∼20 nt in length, are highly conserved 
across species and act as regulators of both genes and 
gene networks [132]. They induce mRNA degrada-
tion and/or inhibit mRNA translation, and it is pre-
dicted that as many as 60% of mRNAs are targets 
for miRNAs [133]. Conversely, long noncoding RNAs 
(lncRNAs) are greater than 200 nt in length and their 
mechanism of action can include regulation of both 
mRNA transcription and/or translation [129], and 
acting as ‘sponges’ for miRNAs [134]. Currently, the 
majority of studies of lncRNAs in the lung have been 
in relation to lung cancer [129].
The study of ncRNAs in disease typically involves 
examining the differential expression of the ncRNAs 
between different patient subsets (e.g., nondisease vs 
disease), concentrating upon a single ncRNA that is 
significantly changed in expression, and targeting said 
ncRNA to inhibit or overexpress its action (exten-
sively reviewed by Booton and Lindsay 2014 [129]). A 
large number of miRNAs are differentially expressed 
in asthma in a predominantly cell-specific manner. 
These include miR-19 in T cells [24], miR-18 in epi-
thelial cells [135] and miR-221 in HASM cells [136]. 
Work examining miRNA profiles show these are 
dramatically different in the bronchial epithelium of 
asthmatics compared with healthy subjects with 217 
differentially expressed miRNA genes [137]. The use of 
corticosteroids (a standard asthma treatment) only had 
a limited effect in restoring normal miRNA expression 
in the asthmatic population, which still retained 200 
differentially expressed genes compared with healthy 
subjects [137].
The role of miRNA in asthma
In addition to studies on primary human cells, many 
current studies defining the potential role of miRNAs 
in asthma utilize mouse models (Table 1). Intrana-
sal administration of miR-1 inhibits inflammatory 
responses to ovalbumin (OVA) and house dust mite 
(HDM) in mouse models of asthma by inhibiting the 
effect of VEGF [138]. VEGF is able to lead to Th2 type 
gene expression and recruitment [138]. In addition, 
miR-145 is as effective as dexamethasone in prevent-
ing airway hyper-responsiveness and inflammation in 
an HDM model of asthma [76]. The same group has 
reported that antagamirs to miR-126 are able to over-
come inflammation and airway hyper-responsiveness 
(AHR) in mouse models of Th2-driven asthma [77] 
and that miR-9 antagamirs can reverse steroid insen-
sitivity by targeting protein phosphatase (PP)2A and 
the glucocorticoid receptor in various mouse models of 
steroid-insensitive asthma [75].
MicroRNAs have also been used as tools to suppress 
target genes in vivo. Intranasal delivery of a siRNA 
against suppressors of cytokine signaling (SOCS3) 
reduces lung eosinophil and airway hyper-responsive-
ness to methacholine following OVA challenge [32]. 
Furthermore, a siRNA directed against CD86, 
involved in T-cell-dendritic cell interactions, inhibit 
OVA-induced hyper-responsiveness, lung eosinophilia 
and serum IgE in mice [139].
Potential asthma therapies targeting miRNA
Utilizing noncoding RNA molecules as novel thera-
pies for treating disease in vivo, is problematic. At 
present there are only two ncRNAs in clinical trials. 
A microRNA mimic (MRX34) which inhibits tumor 
growth and increases overall survival in mouse models, 
and is currently in Phase I testing in patients with pri-
mary or metastatic liver cancer [72]. A miR-122 mimic 
is in human clinical trials for hepatitis C [73].
The problems when utilizing miRNAs as a therapy, 
are numerous. For example, modifying miRNAs with 
a locked nucleic acid (LNA) structure, although mak-
ing the miRNA more biologically stable, also activates 
distinct mechanistic pathways, suggesting that toxic-
ity issues may vary drastically with different miRNA 
sequences [140]. To address this issue, attaching ZEN 
(N,N-diethyl-4-(4-nitronaphthalen-1-ylazo)-phe-
nylamine) to both ends of a miRNA considerably 
enhances its binding affinity, results in a greater degree 
of miRNA inhibition and has low toxicity in vitro [140].
Additionally, another limiting factor is determining 
how to reach a sufficient dose within the cell in order 
to achieve efficient miRNA targeting. An imaging-
based analytical method using fluorescence and elec-
tron microscopy to track intracellular transport and 
release of ncRNAs demonstrated that lipid nanopar-
ticles (LNPs) enter cells through clathrin-mediated 
endocytosis and macropinocytosis, and that less than 
2% of the ncRNAs escaped from the endosomes, sug-
gesting that the efficiency of internalization and release 
of ncRNAs is extremely low [141].
This problem may also be overcome, by utilizing 
nanovesicles as delivery vectors [142]. For example, 
nanovesicles containing miR-150 are capable of enter-
ing effector T cells and suppressing allergic contact 
dermatitis (ACD) and promoting antigen-specific tol-
erance in mice [74]. At the time of writing, the human 
application remains unknown.
Finally, the mechanism of action of ncRNAs (both 
miRNAs and lncRNAs) may not be as simple as first 
thought. Evidence suggests that miRNAs may have a 
range of functions, including regulation of transcrip-
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tion through epigenetic mechanisms; of translation by 
acting as decoys and of acting as inhibitors of other long 
noncoding RNAs [134,143]. Also, lncRNA are thought 
to have a range of mechanisms including regulation of 
both mRNA transcription and/or translation [129], and 
acting as ‘sponges’ for miRNAs [134]. Therefore, using 
ncRNAs as a potential therapy may produce numerous 
‘off-target effects’. That said, improved techniques for 
targeting ncRNAs, and increasing knowledge of their 
biological function could lead to the production of spe-
cific gene expression modulators for respiratory disease 
in the future.
Conclusion
Asthma is a heterogeneous disease of the airways, 
which in cases of severe asthma is currently untreat-
able. Asthma has both environmental and heritable 
components, which has not been directly linked to 
specific genes, implying control through epigenetic 
mechanisms, which can regulate cell fate, secretion 
profiles, inflammation and proliferation.
At present study into the role of epigenetics in 
the development and maintenance of asthma is in 
its infancy. As new epigenetic tools and techniques 
become available, the role of different epigenetic 
mechanisms in asthma is becoming better understood, 
and may potentially allow for the future development 
of novel treatments for asthma. The dynamic nature 
of epigenetic modifications, which unlike DNA modi-
fications can be reversed, offers hope that as some 
patients ‘grow out’ of asthma, a similar cure for asthma 
could be developed in the future.
The biggest challenge facing the development of epi-
genetic-based therapies for asthma, and other diseases, is 
the broad actions of the epigenetic modifying enzymes, 
which have multiple potential targets. Many of the exist-
ing early tool compounds are broadly active and there-
fore will have many undesired side effect proteins, how-
ever as our understanding of these enzymes increases so 
will specificity of the drugs which are available.
Recent developments in genome targeting tools, 
such as the development of CRISPR (clustered regu-
larly interspaced short palindromic repeats) – Cas9, to 
provide highly selective RNA-guided endonucleases 
to modify the genome at specific sites [144], is overtak-
ing standard genetic knockdown approaches in mice. 
This technology has been used successfully in vivo and 
allows specific targeting of DNA sequences and their 
associated epigenetic marks which can be directed at 
potentially clinically useful sites.
Many of the targets for epigenetic therapeutics need 
to be targeted to specific genes and areas of the genome. 
Drugs that inhibit DNA methylation are able to target 
specific regions of the genome as the methylases bind to 
transcription factors that bind specific regions of DNA. 
If a similar mechanism could be found to target genes 
such as histone modifiers then the degree of usefulness of 
many of these drugs would increase. While there is a long 
way to go, the future looks bright for new treatments for 
asthma based on epigenetics. New compounds will offer 
the possibility to investigate epigenetic pathways and 
may lead to a novel therapeutic direction of research.
Future perspective
Knowledge of the role of epigenetics in asthma will con-
tinue to grow and the links between asthma and specific 
combinations of epigenetic modifications will become 
clearer. As the cost of ChIP-sequencing and next-gen-
eration sequencing decreases, the affordability of inves-
tigating multiple epigenetic modifications and how 
they relate to gene and protein expression will increase. 
Investigating the role of epigenetic modifications will 
also become easier due to technological advances allow-
ing much more complicated studies to be conducted 
with fewer primary cells from each patient.
Studies are beginning to allow the investigation of 
how the epigenome changes over time particularly in 
response to environmental exposures. Changes in DNA 
methylation linked to SNP analysis (EWAS, epig-
enome-wide association studies) and deconvolution 
of transcriptomic data in single cell types may allow 
for greater determination of important targets for sub-
sets of asthma. Linking these studies to longitudinal 
methylation analysis (LEWAS) will allow even greater 
insight into how environmental challenges may affect 
disease onset. Similar studies in blood, airway epithe-
lial cells or smooth muscle cells focused on histone 
modifications or chromatin structure using ChIP-seq 
or ACAT-seq approaches may be of even greater benefit 
and help define new animal models or targets that will 
define the potential therapeutic benefits of drugs that 
target epigenetic mechanisms.
In terms of therapeutics, the technology for deliver-
ing miRNAs and other epigenetic drugs to the lungs 
will improve and provide a greater therapeutic window. 
Currently, targeting of epigenetic drugs to specific sites 
is more advantageous with DNA methylation but 
it is hoped that selective targeting will enable higher 
specificity of next-generation epigenetic drugs.
Current epigenetic drugs are really tool compounds 
which have off-target effects which limit their options 
for clinical trials. Animal models will be useful for 
pharmacokinetic studies but may lack the correct epi-
genetic components of human cells and tissues to allow 
predictive studies. The option of topical delivery to the 
airways and the development of highly lung resident 
drugs with very low systemic exposure may improve 
the chances of successful clinical studies in asthma.
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•	 Asthma is a heritable heterogeneous disease of the airways and severe asthma currently has no treatment.
•	 Epigenetics may account of the heritability of asthma through histone modifications, DNA methylation and 
interfering RNA.
•	 There are now a variety of tools available to target many epigenetic mechanisms.
•	 Modifying acetylation and methylation of histones and DNA methylation can change expression of 
inflammatory genes.
•	 DNA methylation modifiers can be targeted at particular regions of DNA as they are bound to specific 
complexes which allow specificity of drugs.
•	 miRNA treatments such as suppressors of cytokine signaling (SOCS3) siRNA are able to be targeted specifically 
to the lung and can reduce eosinophilia.
•	 Further work is required before these drugs progress into human clinical trials.
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